Switch theme
Sign up to access all valuation multiples
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.
2006
24
LTM Revenue $2.4M
LTM EBITDA -$22.7M
$9.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biophytis has a last 12-month revenue (LTM) of $2.4M and a last 12-month EBITDA of -$22.7M.
In the most recent fiscal year, Biophytis achieved revenue of n/a and an EBITDA of -$17.8M.
Biophytis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biophytis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$22.7M | XXX | -$17.8M | XXX | XXX | XXX |
| EBITDA Margin | -963% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$22.7M | XXX | -$16.9M | XXX | XXX | XXX |
| EBIT Margin | -963% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$21.8M | XXX | -$20.1M | XXX | XXX | XXX |
| Net Margin | -925% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Biophytis's stock price is EUR 0 (or $0).
Biophytis has current market cap of EUR 2.9M (or $3.4M), and EV of EUR 7.8M (or $9.2M).
See Biophytis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.2M | $3.4M | XXX | XXX | XXX | XXX | $-3.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Biophytis has market cap of $3.4M and EV of $9.2M.
Biophytis's trades at n/a EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate Biophytis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biophytis has a P/E ratio of -0.2x.
See valuation multiples for Biophytis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.4M | XXX | $3.4M | XXX | XXX | XXX |
| EV (current) | $9.2M | XXX | $9.2M | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/FCF | -0.4x | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiophytis's last 12 month revenue growth is 1028%
Biophytis's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.7M for the same period.
Biophytis's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biophytis's rule of X is 1607% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biophytis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1028% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -963% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -91% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 1607% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biophytis acquired XXX companies to date.
Last acquisition by Biophytis was XXXXXXXX, XXXXX XXXXX XXXXXX . Biophytis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biophytis founded? | Biophytis was founded in 2006. |
| Where is Biophytis headquartered? | Biophytis is headquartered in France. |
| How many employees does Biophytis have? | As of today, Biophytis has 24 employees. |
| Who is the CEO of Biophytis? | Biophytis's CEO is Mr. Stanislas Veillet. |
| Is Biophytis publicy listed? | Yes, Biophytis is a public company listed on PAR. |
| What is the stock symbol of Biophytis? | Biophytis trades under ALBPS ticker. |
| When did Biophytis go public? | Biophytis went public in 2015. |
| Who are competitors of Biophytis? | Similar companies to Biophytis include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Biophytis? | Biophytis's current market cap is $3.4M |
| What is the current revenue of Biophytis? | Biophytis's last 12 months revenue is $2.4M. |
| What is the current revenue growth of Biophytis? | Biophytis revenue growth (NTM/LTM) is 1028%. |
| What is the current EV/Revenue multiple of Biophytis? | Current revenue multiple of Biophytis is 3.9x. |
| Is Biophytis profitable? | Yes, Biophytis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biophytis? | Biophytis's last 12 months EBITDA is -$22.7M. |
| What is Biophytis's EBITDA margin? | Biophytis's last 12 months EBITDA margin is -963%. |
| What is the current EV/EBITDA multiple of Biophytis? | Current EBITDA multiple of Biophytis is -0.4x. |
| What is the current FCF of Biophytis? | Biophytis's last 12 months FCF is -$21.9M. |
| What is Biophytis's FCF margin? | Biophytis's last 12 months FCF margin is -930%. |
| What is the current EV/FCF multiple of Biophytis? | Current FCF multiple of Biophytis is -0.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
